Research programme: mucosal-penetrating aciclovir - Kala PharmaceuticalsAlternative Names: Aciclovir-MPP
Latest Information Update: 16 Jul 2016
At a glance
- Originator Kala Pharmaceuticals
- Class Hypoxanthines
- Mechanism of Action DNA-directed DNA polymerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Herpes simplex virus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Herpes-simplex-virus-infections(Prevention) in USA (Vaginal)
- 13 Jul 2012 Preclinical trials in Herpes simplex virus infections prevention in USA (Vaginal)